Logo Logo
Switch Language to German
Powles, Thomas; Albiges, Laurence; Stähler, Michael; Bensalah, Karim; Dabestani, Saeed; Giles, Rachel H.; Hofmann, Fabian; Hora, Milan; Kuczyk, Markus A.; Lam, Thomas B.; Marconi, Lorenzo; Merseburger, Axel S.; Fernandez-Pello, Sergio; Tahbaz, Rana; Volpe, Alessandro; Ljungberg, Borje; Bex, Axel (2018): Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. In: European Urology, Vol. 73, No. 3: pp. 311-315
Full text not available from 'Open Access LMU'.


The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the combination of ipilimumab and nivolumab when compared with the previous standard of care in first-line metastatic/advanced clear cell renal cell carcinoma (RCC) (Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naive advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. LBA5, ESMO 2017, 2017). These results change the frontline standard of care for this disease and have implications for the selection of subsequent therapies. For this reason the European Association of Urology RCC guidelines have been updated. Patient summary: The European Association of Urology guidelines will be updated based on the results of the phase III Checkmate-214 clinical trial. The trial showed superior survival for a combination of ipilimumab and nivolumab (IN), compared with the previous standard of care, in intermediate-and poor-risk patients with metastatic clear cell renal cell carcinoma. When IN is not safe or feasible, alternative agents such as sunitinib, pazopanib, and cabozantinib should be considered. Furthermore, at present, the data from the trial are immature in favourable-risk patients. Therefore, sunitinib or pazopanib remains the favoured agent for this subgroup of patients.